WO2000021575A3 - Inhibiteurs de calpaine et applications de ces inhibiteurs - Google Patents

Inhibiteurs de calpaine et applications de ces inhibiteurs Download PDF

Info

Publication number
WO2000021575A3
WO2000021575A3 PCT/US1999/021453 US9921453W WO0021575A3 WO 2000021575 A3 WO2000021575 A3 WO 2000021575A3 US 9921453 W US9921453 W US 9921453W WO 0021575 A3 WO0021575 A3 WO 0021575A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
provides
calpain inhibitor
administration
cell
Prior art date
Application number
PCT/US1999/021453
Other languages
English (en)
Other versions
WO2000021575A2 (fr
Inventor
Isabella A Atencio
Drake M Laface
Muralidhara Ramachandra
Paul W Shabram
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Priority to AU10926/00A priority Critical patent/AU1092600A/en
Publication of WO2000021575A2 publication Critical patent/WO2000021575A2/fr
Publication of WO2000021575A3 publication Critical patent/WO2000021575A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1758—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne un procédé qui permet d'accroître l'apoptose dans une cellule et qui consiste à administrer du p53 combiné à un inhibiteur de calpaïne. Cette invention concerne également un procédé qui permet d'accroître l'infectivité d'une cellule par un vecteur viral et qui consiste à traiter la cellule à l'aide d'un inhibiteur de calpaïne. Cette invention concerne en outre un procédé permettant d'accroître la transcription d'un transgène thérapeutique à partir du promoteur CMV. Cette invention concerne aussi un procédé permettant de supprimer la réponse CTL in vivo à des vecteurs viraux à l'aide d'inhibiteurs de calpaïne. Cette invention concerne également des formulations pharmaceutiques de p53 et d'un inhibiteur de calpaïne dans un excipient acceptable sur le plan pharmaceutique. Cette invention concerne aussi un procédé d'ablation in vivo de cellules néoplastiques dans l'organisme d'un mammifère, lequel consiste à effectuer l'administration conjuguée d'un inhibiteur de calpaïne et de p53. Cette invention concerne enfin un procédé d'ablation de cellules néoplastiques ex vivo dans une population de cellules normales qui a été contaminée par lesdites cellules néoplastiques, lequel procédé consiste à administrer une combinaison d'un adénovirus recombinant et d'un inhibiteur de calpaïne à ladite population.
PCT/US1999/021453 1998-10-15 1999-10-14 Inhibiteurs de calpaine et applications de ces inhibiteurs WO2000021575A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU10926/00A AU1092600A (en) 1998-10-15 1999-10-14 Calpain inhibitors and their applications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17268598A 1998-10-15 1998-10-15
US09/172,685 1998-10-15

Publications (2)

Publication Number Publication Date
WO2000021575A2 WO2000021575A2 (fr) 2000-04-20
WO2000021575A3 true WO2000021575A3 (fr) 2000-11-23

Family

ID=22628752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/021453 WO2000021575A2 (fr) 1998-10-15 1999-10-14 Inhibiteurs de calpaine et applications de ces inhibiteurs

Country Status (3)

Country Link
AR (1) AR020896A1 (fr)
AU (1) AU1092600A (fr)
WO (1) WO2000021575A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030060435A1 (en) 1994-05-31 2003-03-27 Serge Carillo Method of cancer treatment by p53 protein control
WO2002010768A2 (fr) 2000-07-31 2002-02-07 The Regents Of The University Of California Modele pour la maladie d'alzheimer et autres maladies neurodegenerative

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EASTHAM J A ET AL: "IN VIVO GENE THERAPY WITH P53 OR P21 ADENOVIRUS FOR PROSTATE CANCER", CANCER RESEARCH,US,AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 55, no. 22, 15 November 1995 (1995-11-15), pages 5151 - 5155, XP000606345, ISSN: 0008-5472 *
HAMADA KATSUYUKI ET AL: "Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer.", CANCER RESEARCH 1996, vol. 56, no. 13, 1996, pages 3047 - 3054, XP002137540, ISSN: 0008-5472 *
KUBBUTAT M H ET AL: "Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability.", MOLECULAR AND CELLULAR BIOLOGY, (1997 JAN) 17 (1) 460-8., XP000906747 *
LIU T -J ET AL: "APOPTOSIS INDUCTION MEDIATED BY WILD-TYPE P53 ADENOVIRAL GENE TRANSFER IN SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK", CANCER RESEARCH,US,AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 55, 15 July 1995 (1995-07-15), pages 3117 - 3122, XP002027381, ISSN: 0008-5472 *
PARIAT M ET AL: "Proteolysis by calpains: a possible contribution to degradation of p53", MOLECULAR AND CELLULAR BIOLOGY,US,WASHINGTON, DC, vol. 17, no. 5, May 1997 (1997-05-01), pages 2806 - 2815, XP002110841, ISSN: 0270-7306 *
SHINOHARA K ET AL: "Apoptosis induction resulting from proteasome inhibition.", BIOCHEMICAL JOURNAL, (1996 JUL 15) 317 ( PT 2) 385-8., XP000906742 *

Also Published As

Publication number Publication date
AU1092600A (en) 2000-05-01
AR020896A1 (es) 2002-06-05
WO2000021575A2 (fr) 2000-04-20

Similar Documents

Publication Publication Date Title
Cao et al. Adenoviral vectors for gene replacement therapy
Eto et al. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability
EP1109914B1 (fr) L'heme oxygenase (1) pour l'inhibition de la migration des cellules des muscles
EP0797436A4 (fr) Nouveaux vecteurs adenoviraux, lignees cellulaires d'encapsidation, adenovirus recombines et procedes
CA2152941A1 (fr) Virus cytopathiques pour le traitement et la prevention des neoplasmes
WO1997012986A3 (fr) Vecteurs adenoviraux n'appartenant pas au groupe c
WO2000012740A3 (fr) ADENOVIRUS A DELETIONS DANS LES SEQUENCES IVa2, 100K ET/OU DE PROTEINES PRETERMINALES
AU5152998A (en) Improved adenovirus vectors
MX9706485A (es) Metodos y composiciones para terapia de genes para tratamiento de defectos en el metabolismo de lipoproteina.
MX9800025A (es) Virus mva recombinante, y su empleo.
WO1995032298A3 (fr) Vecteurs surs pour therapie genique
DK1681355T3 (da) Sekvensspecifik DNA-rekombination i eukaryote celler
DE69636863D1 (de) Benutzung von immunmodulatoren zur herstellung von medikamenten zur inhibierung einer immunantwort gegen gleichzeitig verabreichte rekombinante viren
WO1998029555A3 (fr) Virus cytopathogenes pour le traitement et la prophylaxie de la neoplasie
CA2051289A1 (fr) Destruction de cellules neoplasiques a l'aide d'un virus
AU4723596A (en) Method for preparing a recombinant adenovirus genome
JP2004501650A5 (fr)
Ushitora et al. Prevention of hepatic ischemia–reperfusion injury by pre-administration of catalase-expressing adenovirus vectors
WO1994006449A3 (fr) Regeneration du foie induite par des morphogenes
WO2002006451A1 (fr) Vecteur de therapie genique d'auto-inactivation specifique d'un tissu
EP1070122A4 (fr) Induction de l'expression de genes apoptotiques ou cytotoxiques par co-apport de genes a mediation adenovirale
WO2000010550A3 (fr) Reduction de l'inactivation des surfactants utilises en therapie pulmonaire par surfactants
HK1043812B (zh) 含有外源5'非翻譯區作爲轉錄調控元件的哺乳動物表達載體
WO2000021575A3 (fr) Inhibiteurs de calpaine et applications de ces inhibiteurs
EP1144009A3 (fr) Excipients a utiliser dans des preparations pharmaceutiques a base de particules virales associees aux adenovirus, et preparations pharmaceutiques realisees avec ces excipients

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 10926

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase